Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy

Cancer Immunology, Immunotherapy

Volumn 66, Issue 11, 2017, Pages 1473-1484

  Sander, Frida Ewald ^a   Nilsson, Malin ^a   Rydström, Anna ^a   Aurelius, Johan ^a,b   Riise, Rebecca E ^a   Movitz, Charlotta ^a   Bernson, Elin ^a   Kiffin, Roberta ^a   Ståhlberg, Anders ^c   Brune, Mats ^b   Foà, Robin ^d   Hellstrand, Kristoffer ^a   Thorén, Fredrik B ^a   Martner, Anna ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; IL 2; Immunotherapy; Regulatory T cells

Indexed keywords

ALDESLEUKIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HISTAMINE; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL OUTCOME; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; GENE LOCUS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STAINING; TELOMERE LENGTH; TREATMENT OUTCOME; ACUTE DISEASE; ADOLESCENT; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; STATISTICS AND NUMERICAL DATA; TELOMERE; TUMOR RECURRENCE; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTAMINE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TELOMERE; YOUNG ADULT;

EID: 85024499249     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2040-9     Document Type: Article

References (61)

1. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK (2005) Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 202:1375–1386
2. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6:1219–1227
3. Yadav M, Stephan S, Bluestone JA (2013) Peripherally induced tregs—role in immune homeostasis and autoimmunity. Front Immunol 4:232
4. Haribhai D, Williams JB, Jia S et al (2011) A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 35:109–122
5. Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13
6. Lapierre P, Lamarre A (2015) Regulatory T cells in autoimmune and viral chronic hepatitis. J Immunol Res 2015:479703
7. Littwitz-Salomon E, Akhmetzyanova I, Vallet C, Francois S, Dittmer U, Gibbert K (2015) Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection. Retrovirology 12:66
8. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307
9. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX (2005) Intratumor depletion of CD4 + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779–791
10. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117
11. Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179
12. Lai C, August S, Behar R, Polak M, Ardern-Jones M, Theaker J, Al-Shamkhani A, Healy E (2015) Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis. Lancet 385(Suppl 1):S59
13. Wolf D, Wolf AM, Rumpold H et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326–8331
14. Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute Myeloid Leukemia. N Engl J Med 373:1136–1152
15. Martner A, Thoren FB, Aurelius J, Hellstrand K (2013) Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev 27:209–216
16. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, Xi X (2011) Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 129:1373–1381
17. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 15:3325–3332
18. Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, Hirst WJ (2001) Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 167:6021–6030
19. Costello RT, Sivori S, Marcenaro E et al (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99:3661–3667
20. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323–330
21. Aurelius J, Thoren FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K, Martner A (2012) Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. Blood 119:5832–5837
22. Hellstrand K, Asea A, Dahlgren C, Hermodsson S (1994) Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 153:4940–4947
23. Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K (2000) Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 96:1961–1968
24. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K (1996) NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 57:312–319
25. Asea A, Hermodsson S, Hellstrand K (1996) Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 43:9–15
26. Kolitz JE, George SL, Benson DM Jr et al (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010–1017
27. Baer MR, George SL, Caligiuri MA et al (2008) Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and Leukemia Group B Study 9720. J Clin Oncol 26:4934–4939
28. Blaise D, Attal M, Reiffers J et al (2000) Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 11:91–98
29. Pautas C, Merabet F, Thomas X et al (2010) Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 28:808–814
30. Lange BJ, Smith FO, Feusner J et al (2008) Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood 111:1044–1053
31. Mao C, Fu XH, Yuan JQ et al (2015) Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database Syst Rev 11:CD010248
32. Brune M, Castaigne S, Catalano J et al (2006) Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108:88–96
33. Campbell DJ (2015) Control of regulatory T cell migration, function, and homeostasis. J Immunol 195:2507–2513
34. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500
35. Kennedy-Nasser AA, Ku S, Castillo-Caro P et al (2014) Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 20:2215–2225
36. Kim N, Jeon YW, Nam YS, Lim JY, Im KI, Lee ES, Cho SG (2015) Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine 78:22–26
37. Koreth J, Matsuoka K, Kim HT et al (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055–2066
38. Matsuoka K, Koreth J, Kim HT et al (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5:179ra43
39. Sander FE, Rydström A, Bernson E et al (2016) Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget 7:7586–7596
40. Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foa R, Hellstrand K, Thoren FB (2016) Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology 5:e1041701
41. Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foa R, Hellstrand K, Thoren FB (2015) NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget 6:42569–42574
42. Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474
43. Baron U, Floess S, Wieczorek G et al (2007) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37:2378–2389
44. Bennett CL, Christie J, Ramsdell F et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21
45. Cawthon RM (2009) Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 37:e21
46. Morikawa H, Sakaguchi S (2014) Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol Rev 259:192–205
47. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM (2010) Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells. J Immunol 184:3433–3441
48. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3 + regulatory T cell function. Science 322:271–275
49. Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M (2014) Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res 38:964–969
50. Moon HW, Kim BH, Park CM, Hur M, Yun YM, Kim SY, Lee MH (2011) CD4 + CD25highFoxP3 + regulatory T-cells in hematologic diseases. Korean J Lab Med 31:231–237
51. Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM (2011) IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3 + T cells in vivo. J Immunol 186:6329–6337
52. Wen Z, Shimojima Y, Shirai T, Li Y, Ju J, Yang Z, Tian L, Goronzy JJ, Weyand CM (2016) NADPH oxidase deficiency underlies dysfunction of aged CD8 + Tregs. J Clin Invest 126:1953–1967
53. Martelli MF, Di Ianni M, Ruggeri L et al (2014) HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124:638–644
54. Fessler J, Ficjan A, Duftner C, Dejaco C (2013) The impact of aging on regulatory T-cells. Front Immunol 4:231
55. Bär C, Blasco MA (2016) Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000Res. 5. eCollection 2016
56. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, Wheatley K, Hunter A, Russell N (2013) Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 31:1293–1301
57. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR, Murphy WJ (2008) Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transpl 14:1088–1099
58. Bachanova V, Cooley S, Defor TE et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855–3863
59. Arenas-Ramirez N, Woytschak J, Boyman O (2015) Interleukin-2: biology, design and application. Trends Immunol 36:763–777
60. Votavova P, Tomala J, Kovar M (2014) Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Ralpha-Fc chimera. Immunol Lett 159:1–10
61. Perna SK, De Angelis B, Pagliara D et al (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19:106–117